NCT04681092View on ClinicalTrials.gov

Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

March 10, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

AKS-452

s.c. or i.m. vaccination

Trial Locations (1)

9700 RB

University Medical Center Groningen, Groningen

Sponsors
All Listed Sponsors
collaborator

Akston Biosciences Corporation

UNKNOWN

lead

University Medical Center Groningen

OTHER